Insmed Lags on Q4 Earnings, Stock Gains on 2026 Brinsupri Sales View

INSM shares jump 7% as Brinsupri sales surge and 2026 outlook calls for at least $1B, despite a wider Q4 loss and rising expenses.

Zacks Investment Research • Feb 20, 2026

Wall Street Analysts Think Insmed (INSM) Could Surge 33.6%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Insmed (INSM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Feb 20, 2026

Insmed Incorporated (INSM) Q4 2025 Earnings Call Transcript

Insmed Incorporated (INSM) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 19, 2026

Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update

—Company Expects Full-Year 2026 BRINSUPRI® (brensocatib) Revenues to Be at Least $1 Billion; Reiterates Full-Year 2026 ARIKAYCE ® (amikacin liposome inhalation suspension) Revenue Guidance of $450 Million to $470 Million— —Total Company Revenues of $606.4 Million for Full-Year 2025— —BRINSUPRI Total Revenues of $144.6 Million for Fourth-Quarter and $172.7 Million for Full-Year 2025— —ARIKAYCE Total Revenues of $119.2 Million for Fourth-Quarter and $433.8 Million for Full-Year 2025, Representing 19% Annual Growth and Exceeding the Upper End of Full-Year 2025 Guidance— —Topline Data Readouts from Phase 3 ENCORE and Phase 2b CEDAR Studies Remain on Track— —FDA grants Orphan Drug Designation to Treprostinil Palmitil for Treatment of PAH— —Company Ends 2025 with Approximately $1.4 Billion of Cash, Cash Equivalents, and Marketable Securities— BRIDGEWATER, N.J., Feb. 19, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.

PRNewsWire • Feb 19, 2026

Insmed (INSM) Reports Q4 Earnings: What Key Metrics Have to Say

The headline numbers for Insmed (INSM) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Feb 19, 2026

Insmed (INSM) Reports Q4 Loss, Lags Revenue Estimates

Insmed (INSM) came out with a quarterly loss of $1.54 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $1.32 per share a year ago.

Zacks Investment Research • Feb 19, 2026

What to Expect From These Drug/Biotech Players This Earnings Season?

Let's take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they prepare to report quarterly results this week.

Zacks Investment Research • Feb 16, 2026

Insmed To Present at March 2026 Investor Conferences

BRIDGEWATER, N.J., Feb. 13, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: 46th Annual TD Cowen Healthcare Conference in Boston, on Monday, March 2, 2026, at 9:50 a.m.

PRNewsWire • Feb 13, 2026

Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 12, 2026

Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026

BRIDGEWATER, N.J., Feb. 5, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its fourth-quarter and full-year 2025 financial results on Thursday, February 19, 2026.

PRNewsWire • Feb 5, 2026